In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Dermata Therapeutics Inc (NASDAQ: DRMA) closed the day trading at $1.86 down -21.52% from the previous closing price of $2.37. In other words, the price has decreased by -$21.52 from its previous closing price. On the day, 0.68 million shares were traded. DRMA stock price reached its highest trading level at $2.4 during the session, while it also had its lowest trading level at $1.8.
Ratios:
For a better understanding of DRMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.56 and its Current Ratio is at 4.56. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DRMA now has a Market Capitalization of 1909210 and an Enterprise Value of -2754917.
Stock Price History:
The Beta on a monthly basis for DRMA is 0.53, which has changed by -0.861194 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, DRMA has reached a high of $23.70, while it has fallen to a 52-week low of $1.97. The 50-Day Moving Average of the stock is -38.68%, while the 200-Day Moving Average is calculated to be -69.70%.
Shares Statistics:
Over the past 3-months, DRMA traded about 522.50K shares per day on average, while over the past 10 days, DRMA traded about 2204770 shares per day. A total of 0.84M shares are outstanding, with a floating share count of 0.75M. Insiders hold about 26.85% of the company’s shares, while institutions hold 8.99% stake in the company. Shares short for DRMA as of 1765756800 were 39351 with a Short Ratio of 0.08, compared to 1763078400 on 14002. Therefore, it implies a Short% of Shares Outstanding of 39351 and a Short% of Float of 5.2699998.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.72 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$8.0 and -$8.0 for the fiscal current year, implying an average EPS of -$8.0. EPS for the following year is -$3.01, with 1.0 analysts recommending between -$3.01 and -$3.01.
